Targeting the TGFß pathway with galunisertib, a TGFßRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
J Immunother Cancer
; 6(1): 47, 2018 06 04.
Article
em En
| MEDLINE
| ID: mdl-29866156
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirazóis
/
Quinolinas
/
Fator de Crescimento Transformador beta
/
Terapia Combinada
/
Imunoterapia
Tipo de estudo:
Prognostic_studies
Limite:
Animals
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
J Immunother Cancer
Ano de publicação:
2018
Tipo de documento:
Article